IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and bro...
Since the early hours of Saturday, Israel has witnessed a massive and horrifying assault on innocent lives, leaving hundreds dead, hundreds more injured, a...
Historical Perspective Traditionally, the Middle East's economy has been heavily reliant on its vast reserves of oil and natural gas. However, the region'...
The study will evaluate the safety, tolerability, and efficacy of SCI-210, in comparison to CBD monotherapy in treating ASD. Designed as a randomized, doub...
Patents valid through 2038 Clinical topline results from Phase 2b ALS trial expected in H2 2023 Corresponding patents have b...
“While shocking, this move by Johnson & Johnson is unfortunately not surprising – we demand that the company halt its profiteering tactics ...
In an exclusive interview with Yoav Blat, BARIKS' Representative in North America, we explore the technology behind this chamber and its potential to revol...
The principal investigator, Jennifer Ellis, PhD, Associate Professor of Psychiatry and Behavioral Sciences, JHU School of Medicine will be supported by co-...
MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today anno...
Under the terms of the agreement, Hikma has an exclusive license to commercialise products in Rakuten Medical’s pipeline using its photoimmunotherapy...
ImPact Biotech, a leader in photodynamic therapy, recently announced an agreement with Maastricht University to collaborate in research focused on eye...
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the...
ImPact Biotech, the IMmune Photo Activated Cancer Treatment (IMPACT) specialist announces the U.S. Food and Drug Administrat...
The partners continue working closely on matters concerning pending approval in the U.S. for AVT02, an interchangeable high-concentration biosimilar candid...
© 2024 Biopharma Boardroom. All Rights Reserved.
